TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
Co-inhibitory receptors (IRs) are molecules that protect host against autoimmune reactions and maintain peripheral self-tolerance, playing an essential role in maintaining immune homeostasis. In view of the substantial clinical progresses of negative immune checkpoint blockade in cancer treatment, t...
Main Authors: | Chenran Yue, Sheng Gao, Shuting Li, Zhouhang Xing, Hengrong Qian, Ying Hu, Wenqian Wang, Chunyan Hua |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.911919/full |
Similar Items
-
TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
by: Wenyan Fu, et al.
Published: (2021-03-01) -
A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
by: Zhihao Fu, et al.
Published: (2021-12-01) -
TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
by: Shenhe Jin, et al.
Published: (2022-12-01) -
Studying TIGIT activity against tumors through the generation of knockout mice
by: Ahmed Rishiq, et al.
Published: (2023-12-01) -
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
by: Hauke Stamm, et al.
Published: (2019-12-01)